Psoriasis: characterization of six different clinical phenotypes

Guinot, Christiane; Latreille, Julie; Perrussel, M.; Doss, N.; Dubertret, Louis

doi:10.1111/j.1600-0625.2009.00871.x

Cited by 31 publications

(33 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various pustular forms have also been identified, and symptoms may also include articular inflammation in the case of psoriatic arthritis [1,2]. Psoriasis development is influenced by environmental and genetic factors, and family history [3,4,5]. …”

Section: Introductionmentioning

confidence: 99%

EPIMAG: International Cross-Sectional Epidemiological Psoriasis Study in the Maghreb

Ammar-Khodja

Benkaidali²,

Bouadjar³

et al. 2015

Dermatology

Self Cite

View full text Add to dashboard Cite

Background: Psoriasis is a common skin disorder that is characterized by red plaques covered with silvery scales and is associated with considerable psychosocial impact. It has been described in several studies worldwide, but specific data from the Maghreb (Algeria, Morocco and Tunisia) are unavailable. Objectives: To characterize the frequency of new psoriasis cases and to describe the epidemiological and clinical profile of psoriasis in the Maghreb. Methods: A psoriasis working group for the Maghreb initiated the EPIMAG international multicentre cross-sectional observational epidemiological study coupled with a 2-week psoriasis screening study via medical consultation. Data were collected via questionnaires. Results: The total analysis population included 373 pre-existing and 326 new psoriasis cases, described by 261 participating investigators. The frequency of new psoriasis cases was 10.26/1,000 in Algeria, 15.04/1,000 in Morocco and 13.26/1,000 in Tunisia, and thus 12.08/1,000 in the Maghreb. In all 699 psoriasis subjects, the mean age was 46 years, the mean BMI was 26.6, and 55.7% of subjects were men. Two thirds of the subjects had never smoked, and 85.0% had never consumed alcohol. Half had brown skin, and 28.6% had a family history of psoriasis. Three quarters had localized psoriasis, 85.8% had plaque psoriasis, coupled with pruritus in over 70.0% of cases. Flares or outbreaks were most often triggered by stress (79.4%) and change of season (43.1%). The majority of subjects used topical therapy, and the investigators considered overall treatment efficacy to be partial in over half of the cases. Among patients with pre-existing psoriasis, secondary analyses showed that 73.2% had severe psoriasis, and that quality of life was severely affected in 40.1% of cases. The mean number of missing school or work days over 6 months was 3.2 (±12.1) days. Conclusions: Our study provides novel information relative to psoriasis epidemiology and characterization in the Maghreb and highlights the need to improve psoriasis screening and management in the region. The data will help optimize psoriasis management, to ensure appropriate national health care policies.

show abstract

Section: Introductionmentioning

confidence: 99%

EPIMAG: International Cross-Sectional Epidemiological Psoriasis Study in the Maghreb

Ammar-Khodja

Benkaidali²,

Bouadjar³

et al. 2015

Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of these, 40 of 41 patients (98%) in the adalimumab group and 13 of 17 patients (77%) in the placebo group (switched to adalimumab) completed the open-label extension period (weeks [17][18][19][20][21][22][23][24][25][26][27][28]. The most frequent primary reason for discontinuation during each period was an adverse event.…”

Section: Resultsmentioning

confidence: 99%

“…As shown in Figure 1, the study was divided into 2 periods: the placebo-controlled period (week 0-16) and the extension period (week [17][18][19][20][21][22][23][24][25][26][27][28]. During the placebo-controlled period, enrolled patients were randomized in a 2:1 ratio to receive either active adalimumab (initial dose of two 40-mg injections subcutaneously [SC] at week 0 followed by 40 mg SC every other week from week 1 to 15) or matching placebo (2 injections SC at week 0 followed by 1 placebo injection SC every other week from week 1 to 15).…”

Section: Methodsmentioning

confidence: 99%

Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet

Leonardi

Langley²,

Papp³

et al. 2011

Arch Dermatol

View full text Add to dashboard Cite

To determine the efficacy, safety, and sustainability of response to adalimumab therapy for moderate to severe chronic plaque psoriasis involving hands and/or feet.Design: Sixteen-week, randomized, double-blind, placebo-controlled evaluation of adalimumab therapy for moderate to severe chronic plaque psoriasis involving the hands and/or feet with a 12-week open-label extension (Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet [REACH]).Setting: Multicenter outpatient study in the United States and Canada.Participants: Patients with chronic plaque psoriasis on the hands and/or feet with a Physician's Global Assessment of hands and/or feet (hfPGA) score of "moderate" or above.Intervention: Patients were randomized 2:1 to adalimumab (80 mg at week 0, then 40 mg every other week starting at week 1) or to matching placebo.Main Outcome Measure: Percentage of patients achieving an hfPGA score of "clear" or "almost clear" at week 16.Results: Seventy-two patients (adalimumab [n = 49]; placebo [n=23]) were evaluated. Baseline percentages of patients with moderate and severe hfPGA scores were 76% and 24%, respectively, for the adalimumab group and 74% and 26%, respectively, for the placebo group. At week 16, 31% and 4% of patients randomized to adalimumab and placebo, respectively, achieved an hfPGA score of clear or almost clear (P =.01). At week 28, 80% of the hfPGA clear or almost clear response was maintained from week 16 (25% for patients randomized to adalimumab). Adverse events in both groups were generally mild to moderate. In both periods combined, nasopharyngitis (27% and 13% for adalimumab-and placebo-treated patients, respectively) was most frequently reported. Conclusion:Adalimumab is efficacious and well tolerated for treatment of chronic plaque psoriasis of hands and/or feet, with efficacy largely maintained to 28 weeks.

show abstract

“…On the other hand, psoriatic tattooed patients may treat themselves using local ointments without seeking additional medical consultation. Furthermore, the frequency of KP varies with the clinical phenotypes of psoriasis . The extent and activity of psoriasis at the time of tattooing are additional factors involved .…”

Section: Discussionmentioning

confidence: 99%